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We describe a mechanism of tumorigenesis medi-
ated by kinase-dead BRAF in the presence of onco-
genic RAS. We show that drugs that selectively
inhibit BRAF drive RAS-dependent BRAF binding to
CRAF, CRAF activation, and MEK–ERK signaling.
This does not occur when oncogenic BRAF is
inhibited, demonstrating that BRAF inhibition per se
does not drive pathway activation; it only occurs
when BRAF is inhibited in the presence of oncogenic
RAS. Kinase-dead BRAF mimics the effects of the
BRAF-selective drugs and kinase-dead Braf and
oncogenic Ras cooperate to induce melanoma in
mice. Our data reveal another paradigm of BRAF-
mediated signaling that promotes tumor progres-
sion. They highlight the importance of understanding
pathway signaling in clinical practice and of genotyp-
ing tumors prior to administering BRAF-selective
drugs, to identify patients who are likely to respond
and also to identify patients who may experience
adverse effects.
INTRODUCTION
The RAS–ERK (extracellular-signal regulated protein kinase)
MAPK (mitogen-activated protein kinase) signaling pathway
regulates cell responses to environmental cues (Marshall,
1995) and plays an important role in human cancer (Gray-Schop-
fer et al., 2007). The pathway comprises the RAS small guanine-
nucleotide binding protein and the protein kinases RAF, MEK
(mitogen and extracellular-regulated protein kinase kinase),
and ERK. RAS is attached to the inner face of the plasma
membrane and is activated downstream of growth factor, cyto-
kine, and hormone receptors. Active RAS recruits RAF to the
membrane for activation through a complex process involvingchanges in phosphorylation and binding to other enzymes and
scaffold proteins (Kolch, 2000). RAF phosphorylates and acti-
vates MEK, which phosphorylates and activates ERK.
The complexity of this pathway is increased by the multiplicity
of its components. There are three RAS (HRAS, NRAS, and
KRAS), three RAF (ARAF, BRAF, and CRAF), two MEK (MEK1
and MEK2), and two ERK (ERK1 and ERK2) genes that encode
proteins with nonredundant functions. Furthermore, the pathway
is not linear. BRAF binds to and activates CRAF in a RAS-depen-
dent manner that appears to require CRAF transphosphorylation
by BRAF (Garnett et al., 2005; Rushworth et al., 2006; Weber
et al., 2001), providing subtle pathway regulation that is not
fully understood. ERK phosphorylates many substrates and the
duration and intensity of its activity affects how cells respond
to extracellular signals (Marshall, 1995). Thus, the pathway
must be carefully controlled to ensure appropriate responses to
environmental cues. In normal cells, outcomes include survival,
proliferation, senescence, and differentiation, but in cancer the
constitutive pathway activation favors proliferation and survival.
RAS–ERK signaling is particularly important in melanoma.
Somatic mutations occur in BRAF, NRAS, and KRAS in 43%,
20%, and 2% of melanomas respectively (www.sanger.ac.uk/
genetics/CGP/cosmic/). The mutations in RAS trap it in a GTP-
bound, active conformation and mostly involve glycine 12
(G12), glycine 13 (G13), and glutamine 61 (Q61). A glutamic
acid substitution for the valine at position 600 (V600EBRAF)
accounts for over 90% of the mutations in BRAF in cancer.
However, over 100 other rare mutations have been described,
most of which cluster to the glycine-rich loop and activation
segment in the kinase domain. These regions normally trap
BRAF in an inactive conformation by forming an atypical intra-
molecular interaction, and it is thought that the mutations disrupt
this interaction, thereby allowing the active conformation to
prevail (Wan et al., 2004).
Functional studies have shown that most of the mutations
in BRAF are activating and enhance its ability to directly phos-
phorylate MEK (Wan et al., 2004; Garnett and Marais, 2004).
Curiously however, some mutants have impaired activity andCell 140, 209–221, January 22, 2010 ª2010 Elsevier Inc. 209
although they cannot directly phosphorylate MEK, they appear
to retain sufficient activity to bind to and transphosphorylate
and activate CRAF in a RAS-independent manner (Garnett
et al., 2005), allowing these mutants to activate the pathway indi-
rectly through CRAF. More puzzling are mutations that occur at
aspartic acid 594 (D594). The carboxy oxygen of this highly
conserved residue (the ‘‘D’’ of the DFG motif) plays a critical
role in chelating Mg2+ and stabilizing ATP binding in the catalytic
site (Johnson et al., 1998). As in other kinases, mutation of this
residue causes inactivation and thus cancer mutants such as
D594VBRAF cannot phosphorylate MEK, activate CRAF, or stimu-
late cell signaling (Ikenoue et al., 2003; Wan et al., 2004). These
mutants therefore appear catalytically and biologically inactive
and yet 34 have been found in human cancer (www.sanger.
ac.uk/genetics/CGP/cosmic/). Furthermore, while V600EBRAF
mutations (over 10,000 described) occur in a mutually exclusive
manner with RAS mutations, four of the 34 kinase-dead mutants
are coincident with RAS mutations, a highly significant enrich-
ment (p < 109; Fisher’s Exact Test) that suggests functional
interaction.
It has been shown that V600EBRAF is 500-fold activated, can
stimulates constitutive MEK–ERK signaling in cells (Gray-Schop-
fer et al., 2007) and induce melanoma in mice (Dankort et al.,
2009; Dhomen et al., 2009), showing that it can be a founder
mutation in melanoma. Importantly, V600EBRAF inhibition blocks
melanoma cell proliferation and induces apoptosis in vitro and
blocks melanoma xenograft growth in vivo (see Gray-Schopfer
et al., 2007). These data validate V600EBRAF as a driver of mela-
nomagenesis and as a therapeutic target in melanoma, so drugs
to target this pathway have been developed. The first to be
tested clinically were the multi-kinase inhibitor sorafenib and
the MEK inhibitor PD184352 (CI1040). Disappointingly, both
failed to produce objective responses in patients, either because
they were not sufficiently potent, or because they caused unac-
ceptable toxicity (Halilovic and Solit, 2008). Recently, more
potent and selective BRAF inhibitors have been described. For
example, the triarylimidazole SB590885 and the difluorophenyl-
sulfonamine PLX4720 display excellent selectivity for BRAF
in vitro and preferentially inhibit BRAF mutant cancer cell prolif-
eration (King et al., 2006; Tsai et al., 2008). More importantly,
BRAF-selective drugs have recently entered the clinic and are
producing excellent responses in patients with BRAF mutant
melanoma (Flaherty et al., 2009; Schwartz et al., 2009).
The aim of this study was to better understand the responses
that melanoma cells make to BRAF-selective inhibitors and
thereby to provide a molecular basis for the design of clinical
trials using BRAF drugs. We also wished to examine if kinase-
dead BRAF and oncogenic RAS functionally interact in vivo.
RESULTS
BRAF Inhibitors Activate MEK and ERK in RAS Mutant
Melanoma Cells
We selected four drugs for our studies (Figures S1A–S1D). Sor-
afenib is a class II (inactive conformation binder) drug (Wan et al.,
2004) that inhibits V600EBRAF at 40 nM, CRAF at 13 nM, and
several other kinases in the low nM range (Wilhelm et al.,
2004). It is the least-selective drug that we used. PLX4720 is210 Cell 140, 209–221, January 22, 2010 ª2010 Elsevier Inc.a class I (active conformation binder) inhibitor that is highly selec-
tive and inhibits V600EBRAF at 13 nM (Tsai et al., 2008). 885-A
(Figure S1C) is a close analog of the class I inhibitor SB590885
(King et al., 2006) that is also highly selective for BRAF. It inhibits
V600EBRAF at 2 nM (Figure S1E), is ineffective against a panel of
64 other protein kinases (Table S1), and preferentially blocks
BRAF mutant cancer cell proliferation (Figure S1F). Finally, we
also used the potent and selective MEK inhibitor PD184352
(Sebolt-Leopold et al., 1999).
As expected, all four drugs blocked ERK activity in BRAF
mutant A375 melanoma cells (Figure 1A; see Table S2). Similarly,
all four drugs inhibited ERK in SkMel24, SkMel28, D25, and
WM266.4 cells, another four lines that express mutant BRAF
(Figure S1G). We also tested the drugs in D04, MM415,
MM485, and WM852 NRAS mutant cells (Table S2). As
expected, PD184352 and sorafenib inhibited ERK in all of these
lines (Figure 1A). Surprisingly, however, PLX4720 and 885-A
caused an unexpected increase in ERK activity in the NRAS
mutant cells (Figure 1A). NRAS or CRAF depletion by RNA inter-
ference (RNAi) blocked MEK/ERK activation by PLX4720 and
885-A in NRAS mutant cells (Figure 1B and 1C) and we show
that 885-A activated CRAF in these cells (Figure 1D). We previ-
ously reported that oncogenic RAS requires CRAF but not
BRAF to activate MEK (Dumaz et al., 2006) and consistent with
this, BRAF is inactive in NRAS mutant cells (Figure 1E). These
data therefore present an intriguing paradox. BRAF is not active
and is not required for MEK/ERK activation in RAS mutant cells.
Nevertheless, BRAF inhibitors hyperactivate CRAF and MEK in
these cells, so we studied the underlying mechanism(s).
RAF Inhibitors Induce BRAF Binding to CRAF in RAS
Mutant Cells
Wild-type BRAF binds to CRAF in a RAS-dependent manner and
although this binding is weak, it leads to CRAF activation
(Garnett et al., 2005). Since RAS and CRAF are required for
ERK activation by PLX4720 and 885-A, we investigated if these
drugs induce BRAF binding to CRAF. Endogenous BRAF was
immunoprecipitated from melanoma cells and western blotted
for endogenous CRAF. We show that CRAF did not bind to
BRAF in untreated or PD184352 treated WM852, D04, MM415,
or MM485 cells (Figure 2A), demonstrating that MEK inhibition
does not induce binding. In contrast, sorafenib and 885-A
induced strong binding of BRAF to CRAF in all four lines
(Figure 2A). We also performed the experiment in the inverse
manner, immunoprecipitating CRAF and showing that BRAF
binding was strongly induced by sorafenib and 885-A
(Figure 2A). Curiously, PLX4720 did not appear to induce
BRAF binding to CRAF, but previous studies have shown that
ERK phosphorylates BRAF in a negative-feedback loop that
destabilizes its binding to CRAF (Rushworth et al., 2006). We
show that PD184352 stabilizes BRAF binding to CRAF in the
presence of PLX4720 (Figure 2B), demonstrating that PLX4720
does induce binding, albeit less strongly than the other drugs.
In addition to inducing BRAF binding to CRAF in NRAS mutant
cells, 885-A and sorafenib also induce this binding in
WM1791c melanoma cells and in SW620 and HCT116 colorectal
carcinoma cells (Figure 2C), all of which express mutant KRAS
(Table S2). Importantly, no strong binding of BRAF to CRAF
Figure 1. BRAF Inhibitors Activate CRAF,
MEK, and ERK in RAS Mutant Cell Lines
(A) A375, D04, MM415, MM485, and WM852 cells
were treated with DMSO (), PD184352 (PD;
1 mM), sorafenib (SF; 10 mM), 885-A (1 mM) and
PLX4720 (PLX; 0.3 mM) for 4 hr. Cell extracts
were western blotted for phospho-ERK (ppERK)
and total ERK2 (loading control).
(B and C) D04 cells were transfected with siRNA
against NRAS or CRAF, or control (Mock) as indi-
cated. After 48 hr the cells were treated with
DMSO (), 885-A (1 mM) or PLX4720 (PLX;
0.3 mM) for 4 hr. Cell lysates were western blotted
for NRAS, CRAF, phospho-MEK (ppMEK),
phospho-ERK (ppERK) and tubulin (loading
control).
(D) D04 cells were treated with 885-A for various
times and endogenous CRAF kinase activity
was measured. Data show fold activation of
experimental triplicates compared to untreated
cells with error bars to represent standard devia-
tions from the means.
(E) Endogenous BRAF kinase activity was
measured in A375 or D04 cells. The results (arbi-
trary units per mg of cell protein) are the mean of
an assay performed in triplicate with error bars
to represent standard deviation from the mean.was seen in A375 cells even in the presence of PD184352 and
the drugs did not induce strong BRAF binding to CRAF in two
other BRAF mutant melanoma cell lines (Figure 2D and
Figure S2).
BRAF Binding to CRAF Is Mediated by RAS
Thus, sorafenib, 885-A and PLX4720 all induced BRAF binding
to CRAF in NRAS or KRAS mutant cells, but not in BRAF mutant
cells, showing that BRAF inhibition per se did not induce this
binding; it only occurred when BRAF was inhibited in the pres-
ence of oncogenic RAS. To confirm the essential role of RAS,
we show that a CRAF mutant (R89LCRAF) that cannot bind to
RAS (Fabian et al., 1994) did not bind to BRAF (Figure 3A and
Figure S3A) and the corresponding mutant of BRAF (R188LBRAF)
did not bind to CRAF (Figure 3B and see Figure S3B). We also
prepared membrane/cytosol fractionations of RAS mutant cells
and show that under normal conditions over 40% of CRAF is in
the membrane, whereas BRAF is largely cytosolic (Figure 3C).
Notably, 885-A treatment leads to strong recruitment of BRAF
to the membrane fraction, whereas CRAF is only weakly affected
(Figure 3C). We also show that under normal conditions, EGF did
not induce BRAF binding to CRAF in PMWK cells, a line that is
wild-type for BRAF and RAS (Table S2). However, in the pres-
ence of 885-A, EGF induced robust binding of BRAF to CRAFCell 140, 209–221,in PMWK cells and this resulted in sus-
tained pathway activation (Figure 3D).
This shows that BRAF binding to CRAF
is induced in the presence of both onco-
genic RAS and activated wild-type RAS.
We note that sorafenib and 885-A
induce a mobility shift in BRAF in SDS-gels (Figure 2A). BRAF also undergoes a mobility shift in
PLX4720 treated cells in the presence of PD184352 (Fig-
ure 2B). This mobility shift is reduced when immunoprecipitated
BRAF is treated with calf intestinal alkaline phosphatase
(CIP; Figure 3E) and PD184352 pretreatment reduced, but did
not ablate the magnitude of the shift induced by 885-A
(Figure 3F). Importantly, in vitro CIP treatment and cell pretreat-
ment with PD184352 did not prevent BRAF binding to CRAF
(Figures 3E and 3F). Together, these data suggest that the
BRAF bound to CRAF is hyperphosphorylated through MEK–
ERK-dependent and MEK–ERK-independent mechanisms,
but that this phosphorylation is not required for BRAF binding
to CRAF.
BRAF Inhibition Activates CRAF
To test directly if BRAF binding to CRAF is driven by 885-A
binding to BRAF, we mutated the so-called ‘‘gatekeeper threo-
nine’’ (T529) of BRAF to asparagine (T529N). Since BRAF is not
active in RAS mutant melanoma cells (Figure 1E), we measured
T529NBRAF activity using transient expression in COS cells (Wan
et al., 2004). The results show that T529NBRAF is still activated by
G12VHRAS, G12VNRAS and G12VKRAS (Figure 4A and Figure S4A).
Importantly, T529NBRAF is 170-fold less sensitive to 885-A than
wild-type BRAF (17 nM versus 2869 nM; Figure 4B) and 885-AJanuary 22, 2010 ª2010 Elsevier Inc. 211
Figure 2. BRAF Inhibitors Induce CRAF Binding to BRAF
(A) WM852, D04, MM415 and MM485 cells were treated with DMSO (), PD184352 (PD; 1 mM), sorafenib (SF; 10 mM), 885-A (1 mM) or PLX4720 (PLX; 0.3 mM) for
4 hr. Endogenous BRAF (IP: BRAF) or endogenous CRAF (IP: CRAF) were immunoprecipitated and the immunocomplexes were western blotted (WB) for BRAF or
CRAF. BRAF, and CRAF levels in the cell lysates are also shown.
(B) D04 cells were treated with DMSO (), PD184352 (PD; 1 mM), sorafenib (SF; 10 mM) and PLX4720 (PLX; 0.3mM) for 4 hr. Endogenous CRAF (IP: CRAF) was
immunoprecipitated and the immunocomplexes were western blotted (WB) for BRAF or CRAF. BRAF and CRAF levels in the cell lysates are shown.
(C) SW620, HCT116 and WM1791c cells were treated with DMSO (), PD184352 (PD; 1 mM), sorafenib (SF; 10 mM) or 885-A (1 mM) for 4 hr. Endogenous BRAF (IP:
BRAF) or endogenous CRAF (IP: CRAF) were immunoprecipitated and the immunocomplexes were western blotted (WB) for BRAF or CRAF. The cell lysates were
also blotted for BRAF, CRAF, phospho-ERK (ppERK) and total ERK2 (loading control).
(D) A375 cells were treated with DMSO (), PD184352 (PD; 1 mM), sorafenib (SF; 10 mM), 885-A (1 mM) or PLX4720 (PLX; 0.3 mM) for 4 hr. CRAF (IP: CRAF) was
immunoprecipitated and the immunocomplexes were western blotted (WB) for BRAF or CRAF. BRAF and CRAF levels in the cell lysates are shown.
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did not stimulate its binding to CRAF (Figure 4C), proving that
drug binding to BRAF drives BRAF binding to CRAF.
Next, we expressed a kinase-dead version of BRAF
(D594ABRAF) in D04 cells and show that it forms a constitutive
complex with CRAF (Figure 4D) and that it activates MEK consti-
tutively (Figure 4E, compare lanes 1, 4, and 7). Notably, 885-A
does not further enhance MEK activation driven by D594ABRAF
(Figure 4E, compare lanes 4, 6 to 7, 9), presumably because it
cannot further inhibit this already inactive kinase. Two other
kinase-dead BRAF mutants, the classical catalytic lysine mutant
(K483MBRAF), and D594VBRAF, a mutant found in human cancer
(Wan et al., 2004), also activate MEK in D04 cells (Figure 4F).
Thus, it is BRAF inhibition and not drug binding that drives
BRAF binding to CRAF. This experiment also shows that MEK
activation driven by kinase-dead BRAF is inhibited by sorafenib
(Figures 4E and 4F). Indeed, cell responses to sorafenib appear
to be paradoxical. We show that although sorafenib inhibits
ERK (Figure 1A), it induces BRAF binding to CRAF (Figure 2A),
CRAF activation (Figure 4G) and CRAF phosphorylation on
S338 (Figure 4G, inset), a critical event in CRAF activation
(Mason et al., 1999). To test directly the role of CRAF in cells
when BRAF is inhibited, we mutated its gatekeeper threonine
to asparagine (T421NCRAF). Notably, T421NCRAF still binds to
BRAF in sorafenib and 885-A treated cells (Figure 4H), demon-
strating that drug binding to CRAF is not required for BRAF
binding to CRAF. More importantly, in the presence of
T421NCRAF, sorafenib activates rather than inhibits the pathway
(Figure 4H, compare lanes 3 and 7). We therefore posit that sor-
afenib induces paradoxical activation of CRAF because it inhibits
BRAF and drives CRAF activation, but simultaneously binds to
and inhibits CRAF. In agreement with this model, we show that
two other pan-RAF inhibitors, ZM336372 and RAF265 also
induce BRAF binding to CRAF, but without activating ERK (see
Figure S4B).
Oncogenic Ras and Kinase-Dead Braf Cooperate
to Induce Melanoma in Mice
Our data establish that inhibition of BRAF in the presence of
oncogenic RAS hyperactivates CRAF, MEK, and ERK. To inves-
tigate the consequences of this in vivo, we used conditionally
targeted alleles of oncogenic Kras (KrasLSL-G12D) and kinase-
dead Braf (BrafLSL-D594A) in transgenic mice. These alleles use
Cre-recombinase/LoxP-Stop-LoxP (LSL) technology to regulate
inducible expression of mutant proteins from the endogenous
mouse genes to ensure normal levels of protein expression.
The KrasLSL-G12D allele has been described (Jackson et al.,
2001), and we recently developed theBrafLSL-D594A allele. Briefly,
exon 15 of endogenous Braf was targeted to mutate D594 to
alanine (D594A; see Figure 5A). To prevent expression of
D594ABraf in all cells, an LSL cassette was inserted between
exon 14 and the mutated exon 15. This contains a minigene for
exons 15–18 of WTBraf, a transcription terminator and a NeoR
selection marker to ensure that only WTBraf is expressed.
Removal of the LSL cassette by Cre-recombinase reveals
the mutated exon 15 and D594ABraf is expressed. These
mice were crossed to Tyr::CreERT2 mice (Yajima et al., 2006),
in which the tyrosinase promoter is used to express tamoxifen-
activated Cre-recombinase (CreERT2) in the melanocytes. SinceCreERT2 is activated by tamoxifen, this approach provides
exquisite spatial and temporal control over G12DKras and
D594ABraf expression.
Kras+/LSL-G12D, Braf+/LSL-D594A, and Tyr::CreERT2+/o mice
were crossed to generate Kras+/LSL-G12D;Tyr::CreERT2+/o,
Braf+/LSL-D594A;Tyr::CreERT2+/o, orKras+/LSL-G12D;Braf+/LSL-D594A;
Tyr::CreERT2+/o mice. In all cases, the conditionally targeted
alleles were balanced over a corresponding wild-type allele.
Mice were treated with tamoxifen at 2–3 months of age to induce
mutant protein expression. We have recently shown that in this
model, V600EBraf induces skin hyperpigmentation, nevus forma-
tion, and melanoma (Dhomen et al., 2009). In contrast, D594ABraf
did not induce skin hyperpigmentation, nevi (data not shown)
or tumors (Figure 5C). G12DKras induced weak tail darkening
after 5–6 months (Figure 5B) but did not induce either nevi
(data not shown) or tumors (Figure 5C). However, when D594ABraf
and G12DKras were combined, they induced a conspicuous
skin phenotype. Within 2–3 months the ears (data not shown),
tails (Figure 5B), and paws (Figure 5D) darkened visibly. The
mice did not develop nevi, but within 6 months, they all developed
large, rapidly growing oligo-pigmented tumors (Figures 5C
and 5E). The tumors displayed evidence of ulceration (Figure 5F)
and were composed largely of spindle cells that exhibit
features of malignancy, including cellular atypia, nuclear pleomor-
phism, and conspicuous nucleoli (Figure 5G). They were highly
proliferative as evidenced by large numbers of mitotic figures in
the superficial and deep aspects of the lesions (6 mitosis/
10HPF; Figure 5H) and positive staining for Ki67 throughout
(Figure 5I).
The tumors were strongly and diffusely positive for S100
(Figure 6A) and expressed the melanocyte markers tyrosinase,
Dct, Pax3, and silver (Figure 6B), consistent with a diagnosis of
melanoma. Genomic DNA analysis of the tumors and cell lines
derived from them confirmed thatBrafLSL-D594A had been recom-
bined to BrafLox-D594A (Figure 6C). However, for technical
reasons we could not detect KrasLSL-G12D recombination (data
not shown), so used RT-PCR to amplify and sequence Kras
mRNA. We show that only wild-type Kras is expressed in the
kidneys, whereas the tumors expressed both wild-type Kras
and G12DKras (Figure 6D). Importantly, we show constitutive
binding of Braf to Craf in cells from the G12DKras/D594ABraf
tumors (Figure 6E). As a control, we used cells from melanoma
induced by G12VKras overexpression. Briefly, when G12VKras
was overexpressed in melanocytes in mice using the b-actin
promoter (b-actin:LSL:G12VKras; Meuwissen et al., 2001), it
induced rapid onset melanoma (median time to onset 2 months,
100% penetrance within 3 months) in the absence of D594ABraf
(manuscript submitted). Importantly, in cells from these tumors,
Braf does not bind to Craf (Figure 6E). Thus, it is only kinase-
dead Braf and not wild-type Braf that binds to Craf in the pres-
ence of oncogenic Kras.
DISCUSSION
In this study, we show that inhibition of BRAF by chemical or
genetic means in the presence of oncogenic or growth-factor
activated RAS induces BRAF binding to CRAF, leading to
CRAF hyperactivation and consequently elevated MEK andCell 140, 209–221, January 22, 2010 ª2010 Elsevier Inc. 213
Figure 3. BRAF Binding to CRAF Requires RAS
(A) Myc-epitope tagged CRAF or R89LCRAF (R89L), or an empty vector control (EV) were transfected into D04 cells. After 48 hr, the cells were treated with DMSO
() or 885-A (1 mM) for 4 hr. Myc-tagged CRAF was immunoprecipitated (IP) and the immunocomplexes were western blotted (WB) for endogenous BRAF or myc-
CRAF. Endogenous BRAF and myc-CRAF levels in the cell lysates are also shown.
(B) Myc-epitope tagged BRAF or R188LBRAF (R188L) or an empty vector control (EV) were transfected into D04 cells. After 48 hr the cells were treated with DMSO
() or 885-A (1 mM) for 4 hr. Myc-tagged BRAF was immunoprecipitated (IP) and the immunocomplexes were western blotted (WB) for myc-BRAF or endogenous
CRAF. Myc-BRAF and endogenous-CRAF levels in the cell lysates are also shown.
(C) Membrane or cytosol fractions were prepared from untreated () or 885-A (1 mM) treated D04 cells. BRAF, CRAF, Tubulin (cytosol control) and HRAS
(membrane control) were western blotted in the total lysate (TL), cytosolic fraction (CYT) and membrane fraction (MEM). The graph shows the quantification
of the relative levels of BRAF and CRAF in the membrane and cytosol fractions.
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ERK signaling. The mechanism we describe is another paradigm
of RAF activation downstream of RAS and based on our findings,
we propose the following mechanism by which this occurs. We
posit that in RAS mutant cells, BRAF maintains itself in an inac-
tive conformation through its own kinase activity, either through
auto-phosphorylation, or by phosphorylating a partner protein
that then keeps it inactive (Figure 7A). We are currently using
mass-spectrometry and mutagenic approaches to elucidate
the underlying mechanism. We propose that when BRAF is
inhibited, it escapes this auto-inhibited state and is recruited to
the plasma membrane by RAS, where it forms a stable complex
with CRAF. Critically, we posit that because it is inhibited, BRAF
does not directly phosphorylate MEK, but rather it acts as a
scaffold whose function is to enhance CRAF activation, thereby
allowing CRAF to hyperactivate the pathway (Figure 7B). We do
not know the stoichiometry of the components in these
complexes, but since BRAF and CRAF must both bind to RAS
for complex formation, it seems likely that at least two RAS
proteins are needed to stimulate formation of the complex
(Figure 7B).
It is unclear why PLX4720 only induces weak binding of BRAF
to CRAF, but this may stem from its unique property of displacing
the a-C helix of BRAF when it binds (Tsai et al., 2008) and
suggests that this helix is important for BRAF binding to CRAF,
something that will only be resolved when the BRAF:CRAF
crystal structure is solved. We have attempted to identify other
proteins that may be required to stabilize the BRAF–CRAF
complexes. Our unpublished mutagenesis data suggests that
14-3-3 is required to stabilize these drug-induced complexes
(data not shown) and this is consistent with previous observa-
tions demonstrating that 14-3-3 mediates BRAF binding to
CRAF (Garnett et al., 2005; Rushworth et al., 2006). Although
this appears to contradict our observation that dephosphoryla-
tion does not disrupt the complex, because 14-3-3 binds to
BRAF and CRAF in a phosphorylation-dependent manner, we
presume that 14-3-3 protects these sites from dephosphoryla-
tion. We have also used RNAi to examine the potential role of
other proteins implicated in BRAF-CRAF complex formation or
pathway activation, including the scaffold proteins KSR,
Sprouty2 and RKTG and the small G protein RHEB, but our
preliminary results have not revealed obvious roles for these
proteins. Our studies have parallels to the recently described
heterodimers between DRAF and KSR in Drosophila (Rajakulen-
dran et al., 2009). Notably, flies have only one RAF isoform and
it appears to be an ortholog of BRAF rather than ARAF or
CRAF. Our inability to demonstrate an obvious role for KSR in
mediating BRAF binding to CRAF or CRAF activation by BRAF
suggests that the mechanism underlying dimerization here may
be different from those described in flies, but clearly additional(D) PMWK cells were pretreated with DMSO or 885-A (1 mM, 60 min) and then treat
was immunoprecipitated (IP) and the precipitates were western blotted (WB) for B
pho-MEK (ppMEK), phospho-ERK (ppERK) and total ERK2.
(E) D04 cells were treated with DMSO () or sorafenib (+; 10 mM) for 4 hr. Endogeno
incubated with calf intestinal phosphatase (CIP; 5U, 30C, 30 min) in the presen
western blotted for BRAF and CRAF.
(F) D04 cells were treated with DMSO (), PD184352 (PD; 1 mM) or 885-A (1 mM) f
nocomplexes were western blotted (WB) for BRAF or CRAF. BRAF, CRAF, and pstudies are required to investigate further the role of scaffold
proteins in mediating the phenomena we report.
In contrast to the BRAF-selective inhibitors, the pan-RAF
inhibitors appear to induce paradoxical activation of CRAF.
They induce BRAF binding to CRAF and CRAF activation, but
do not activate MEK–ERK signaling. We posit that this is
because these agents target both BRAF and CRAF. Thus,
although their inhibition of BRAF will stimulate CRAF activation,
they will simultaneously inhibit CRAF (Figure 7C). This model is
supported by our observation that T421NCRAF converts sorafenib
from a pathway inhibitor to a pathway activator and we argue
that the paradoxical activation of CRAF by these inhibitors is
mediated by BRAF, rather than disrupted feedback inhibition
as previously suggested (Hall-Jackson et al., 1999).
Recently, paradoxical activation of PKB/AKT and PKC3 was
also described (Cameron et al., 2009; Okuzumi et al., 2009).
While ATP-competitive inhibition can block kinase function,
they do not block the upstream events that activate the target
kinase. For instance, PKB/AKT inhibitors block the function of
this kinase, but occupation of the ATP-pocket by these inhibitors
was sufficient to induce the priming phosphorylation usually
required for its full activation (Okuzumi et al., 2009). Inhibitor
binding to PKC3 has been shown to have a similar effect
(Cameron et al., 2009). Importantly, the paradoxical activation
of PKB/AKT and PKC3 did not result in pathway activation
because of the continued presence of the inhibitors (Frye and
Johnson, 2009). In contrast, although BRAF inhibitors also block
BRAF kinase activity, this relieves auto-inhibition and results in
BRAF hyperphosphorylation, BRAF binding to CRAF, pathway
activation and oncogenesis, all presumably because BRAF
can heterodimerize with CRAF. Our study also highlights the
critical difference between BRAF-selective and pan-RAF drugs.
Whereas BRAF-selective drugs cause pathway activation in
a RAS-dependent manner, this does not occur with pan-RAF
drugs.
Our results provide important insight into the genetics of
human cancer. Excluding V600 mutants, D594 mutants are the
third most common in BRAF in cancer (34 out of 443 cases or
7.7%; www.sanger.ac.uk/genetics/CGP/cosmic/). Further-
more, as mentioned in the Introduction, while BRAF and RAS
mutations are generally mutually exclusive, 4 of the 34 (11.8%)
tumors with D594 mutations also have mutations in RAS. This
is a highly significant enrichment for the coincidence of these
mutations (p < 109; Fisher’s Exact Test) and suggests a func-
tional interaction. We now provide strong circumstantial
evidence of such an interaction using transgenic mice. By them-
selves, D594ABraf and G12DKras do not induce melanoma, but
they cooperate to induce rapid onset melanoma. This highly
significant result (p < 0.0002) provides a rational explanationed with EGF (10 ng/ml) for the times shown in minutes (min). Endogenous CRAF
RAF and CRAF. The lysates were also western blotted for BRAF, CRAF, phos-
us BRAF was immunoprecipitated and the immunocomplexes left untreated or
ce or absence of phosphatase inhibitors (P’ase Inh). Immunocomplexes were
or 4 hr. Endogenous CRAF (IP: CRAF) was immunoprecipitated and the immu-
hospho-ERK (ppERK) levels in the cell lysates are shown.
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Figure 4. BRAF and Not CRAF Inhibition Drives CRAF Binding to BRAF and CRAF Activation
(A) COS cells were transiently transfected with myc-epitope tagged BRAF, or T529NBRAF (T529N) in the presence of G12VHRAS (RAS) and their kinase activity was
measured. The data represent one assay performed in triplicate, with error bars to represent standard deviations from the mean. Activity (%) is relative to wild-
type BRAF activated by G12VHRAS.
(B) As in (A) but immunocomplexes were treated with DMSO () or 885-A for 10 min prior to measuring their kinase activity. The data represent one assay per-
formed in triplicate, with error bars to represent standard deviations from the mean. Activity (% control) is relative to the untreated kinase.
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Figure 5. Oncogenic Kras and Kinase-Dead
Braf Cooperate to Drive Tumorigenesis
(A) Diagrammatic representation of targeted
conditional BrafLSL-D594A allele used for D594ABraf
expression in mouse melanocytes. The endoge-
nous mouse Braf gene from exons 14–15 is
represented. Exon 15 is mutated to express
D594ABraf (15*). LoxP sites are represented by
triangles. The relative position of the wild-
type BRAF minigene (MG) comprising exons
15–18 of BRAF, the transcription terminator
(term) and the NeoR cassette are shown. Cre-
recombinase mediated removal of these regions
results in BrafLox-D594A, allowing expression of
D594ABraf.
(B) Photographs of the tails of tamoxifen-treated
wild-type (WTKras/WTBraf), Kras+/LSL-G12D;Tyr::
CreERT2+/o (G12DKras/WTBraf), or Kras+/LSL-G12D;
Braf+/LSL-D594A;Tyr::CreERT2+/o (G12DKras/D594ABraf)
mice.
(C) Kaplan-Meier plots showing disease free
progression of study mice. The controls consisted
of 12 tamoxifen-treated Tyr::CreERT2+/o mice;
10 ethanol-treated Braf+/LSL-D594A;Tyr::CreERT2+/o
mice and 6 ethanol-treated Kras+/LSL-G12D; Tyr::
CreERT2+/o mice. The experimental groups con-
sisted of 12 tamoxifen-treated Kras+/LSL-G12D;
Tyr::CreERT2+/o (G12DKras), 24 tamoxifen-
treated Braf+/LSL-D594A;Tyr::CreERT2+/o (D594ABraf)
mice, and 3 tamoxifen-treated Kras+/LSL-G12D;
Braf+/LSL-D594A;Tyr::CreERT2+/o (G12DKras/D594ABraf)
mice.
(D) Photographs of the feet of tamoxifen-treated
wild-type (WTKras/WTBraf), or Kras+/LSL-G12D;
Braf+/LSL-D594A;Tyr::CreERT2+/o (G12DKras/D594ABraf)
mice.
(E) Photograph showing a large tumor on the back of a tamoxifen-treated Kras+/LSL-G12D;Braf+/LSL-D594A;Tyr::CreERT2+/o (G12DKras/D594ABraf) mouse. The fur was
removed to reveal the lesion.
(F) Photomicrograph of a tumor from the back of a G12DKras/D594ABraf mouse. An area of ulceration is highlighted by the arrow.
(G) High magnification photomicrograph of a section of tumor showing atypical cells, conspicuous nucleoli (arrowheads) and nuclear pseudo-inclusions (arrows).
(H) High magnification photomicrograph of a section of tumor showing mitotic figures (arrows).
(I) Photomicrograph of a section of tumor subjected to immunohistochemical analysis with antibodies against Ki67 (MIB1).for the coincidence of these mutations in human cancer. Further-
more, we show that the BRAF inhibitors also hyperactivate this
pathway in growth factor stimulated cells, providing an explana-
tion of why kinase dead BRAF mutations are not always coinci-(C) Myc-epitope tagged BRAF, T529NBRAF (T529N), or an empty vector contro
DMSO () or 885-A (1 mM) for 4 hr. The endogenous CRAF was immunoprecipita
enous CRAF. Myc-BRAF and endogenous CRAF levels in the cell lysates are als
(D) Myc-epitope tagged BRAF, D594ABRAF (D594A), or an empty vector control (E
cipitated (IP) and the immunocomplexes were western blotted for mycBRAF and e
are also shown.
(E) Myc-epitope tagged BRAF, D594ABRAF (D594A), or an empty vector control (EV
(), sorafenib (SF; 10 mM) or 885-A (1 mM) for 4 hr. The cells extracts were western
(loading control). Note that ERK2 runs as a doublet due to the separation of the
(F) Myc-epitope tagged BRAF, K483MBRAF (K483M), D594VBRAF (D594V), D594AB
After 48 hr, the cells were treated with DMSO () or sorafenib (SF; 10 mM) for 4
pho-ERK (ppERK) and CRAF (loading control).
(G) D04 cells were treated with sorafenib (10 mM) for various times and CRAF kinas
bars to represent standard deviations from the means. Inset: D04 cells were treat
blotted for S338 phosphorylation (pS338). CRAF levels in the lysate are shown a
(H) D04 cells stably expressing flag-epitope tagged CRAF (CRAF) or T421NCRAF (T
or 885-A (1 mM) for 4 hr. The flag-CRAF was immunoprecipitated (IP) and the im
Endogenous BRAF, flag-CRAF and phosphorylated ERK (ppERK) levels in the cdent with RAS mutations; presumably in some tumors the coop-
erating mutation is upstream of RAS.
Our results also suggest several potential mechanisms by
which resistance to RAF targeting drugs could develop inl (EV) were transfected into D04 cells. After 48 hr the cells were treated with
ted and the immunocomplexes were western blotted for myc-BRAF or endog-
o shown.
V) were transfected into D04 cells. After 48 hr the myc-BRAF was immunopre-
ndogenous CRAF. Myc-BRAF and endogenous CRAF levels in the cell lysates
) were transfected into D04 cells. After 48 hr the cells were treated with DMSO
blotted for myc-BRAF, phospho-MEK (ppMEK), phospho-ERK and total ERK2
phosphorylated and nonphosphorylated protein.
RAF (D594A), or an empty vector control (EV) were transfected into D04 cells.
hr. Cell extracts were blotted for myc-BRAF, phospho-MEK (ppMEK), phos-
e activity was measured. Data is for one assay performed in triplicate, with error
ed with sorafenib (SF) for 4 hr and CRAF was immunoprecipitated and western
s a loading control.
421N) were treated with DMSO (), PD184352 (PD; 1 mM), sorafenib (SF; 10 mM)
munocomplexes were western blotted for endogenous-BRAF or flag-CRAF.
ell lysates are also shown.
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Figure 6. Tumors Induced by Kinase-Dead Braf andOncogenic Kras
Are Melanoma
(A) Photomicrograph of a section of tumor subjected to immunohistochemical
analysis with antibodies against S100.
(B) RT-PCR analysis revealing expression of tyrosinase (Tyr), Dct, Pax3 and
silver/gp100 (Si) in two independent tumors and kidney (control). GAPDH is
used as a loading control.
(C) PCR-mediated genotyping for wild-type Braf (BrafWT), Braf+/LSL-D594A and
Tyr::CreERT2+/o alleles from a tumor sample, cells derived from the tumor
and from kidney as a control.
(D) PCR amplified fragment for Kras from kidney and tumor samples. Shown
below is the sequencing trace for codons 11–13, together with the DNA and
protein sequence (single amino acid code).
(E) Endogenous CRAF was immunoprecipitated (IP) from cells derived from
a tumor from a G12DKras/D594ABraf mouse (Kras+/LSL-G12D;Braf+/LSL-D594A;Tyr::
CreERT2+/o), or from a tumor from a G12VKras mouse (b-actin+/LSL-G12VKras;
Tyr::CreERT2+/o). The immunocomplexes were western blotted (WB) for Braf
and Craf, and the levels of Braf and Craf in the cell lysates are also shown.patients. BRAF mutant tumors could become resistant to BRAF-
selective drugs, if they acquire a mutation in RAS or an upstream
component that activates RAS, or if the drugs select a population
of cells harboring pre-existing mutations in RAS. Theoretically
this would cause BRAF-mediated CRAF activation, which may
not only induce resistance, but could potentially promote tumor
growth. In line with this, increased expression of CRAF can
mediate acquired resistance to pan-RAF drugs in BRAF mutant
cancer cells in vitro (Montagut et al., 2008), establishing that
CRAF can mediate resistance under some circumstances. Our
in vitro studies also suggest that a potential mechanism of resis-
tance in patients with RAS mutant tumors being treated with218 Cell 140, 209–221, January 22, 2010 ª2010 Elsevier Inc.pan-RAF drugs is acquisition (or selection for cells with pre-
existing mutations) of a CRAF mutation such as a gatekeeper
mutant that prevents drug binding. Again this would potentially
result in BRAF-mediated activation of CRAF (Figure 7D) and
possibly accelerated tumor growth.
Although our studies are restricted to cell lines and transgenic
mice, they do have important immediate clinical implications.
They strongly argue that BRAF-selective inhibitors should not be
administered to patients with RAS mutant tumors, because
long-term use could accelerate tumor growth. Intriguingly,
10%–15% of patients treated with BRAF-selective drugs develop
squamous cell carcinoma (SCC)(Flaherty et al., 2009; Schwartz
et al., 2009). Although MEK–ERK signaling has not yet been
implicated in this response, 22% of SCCs harbour oncogenic
mutations in RAS (9% HRAS, 8% NRAS, 5% KRAS: www.
sanger.ac.uk/genetics/CGP/cosmic/), raising the intriguing pos-
sibility that the BRAF-selective drugs act as tumor promoters in
premalignant skin cells harboring existing mutations in RAS
and/or activation of upstream components that activate RAS.
While sorafenib is equipotent for wild-type and V600EBRAF
(Wilhelm et al., 2004), the BRAF inhibitors we used are approxi-
mately 10-fold more active against V600EBRAF (King et al., 2006;
Tsai et al., 2008). Nevertheless, our data establish that they
target wild-type BRAF in RAS mutant cells. The problem of
mutant v.s. wild-type protein specificity is likely to be difficult
to resolve, because whereas full inhibition of V600EBRAF may
be necessary for clinical response in BRAF mutant tumors, acti-
vation of only a small proportion of wild-type BRAF could be
sufficient to activate the pathway in RAS mutant cells. Thus, to
achieve efficacy against V600EBRAF but avoid activation of
wild-type BRAF in RAS mutant cells, the drugs will need to be
exquisitely selective for the mutant protein. Alternatively, pan-
RAF drugs may be effective because they will target both
V600EBRAF and CRAF activated by BRAF in RAS mutant tumors.
Furthermore, our data suggest that CRAF or MEK selective
drugs should be used in RAS mutant tumors, because they do
not induce BRAF-CRAF complexes and will not activate the
pathway if the tumors acquire mutations such as T421NCRAF
that block drug binding. Perhaps RAF and MEK inhibitors should
be combined to provide the best responses and prevent emer-
gence of resistance, but these issues need to be balanced
against the urgency of the clinical problem being addressed.
In summary, we show that inhibition of BRAF in RAS mutant
cancer cells leads to MEK hyperactivation through CRAF. We
have elucidated another mechanism by which BRAF activates
MEK–ERK signaling, not only to drive tumorigenesis and tumor
progression, but also potentially to allow development of de
novo or acquired resistance to RAF-targeted therapies. Clearly,
BRAF is a remarkably versatile oncogene that can promote
MEK–ERK activation and tumor progression through several
mechanisms and these will require different therapeutic strate-
gies for effective disease management. Notably, many of the
mutations that occur in other kinases in cancer are also pre-
dicted to cause inactivation (www.sanger.ac.uk/genetics/CGP/
cosmic/). Our data raise the possibility that these could also
act as idiosyncratic gain-of-function mutations that drive tumor-
igenesis. This study also raises important clinical questions and
highlights the importance of fully understanding how signaling
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Figure 7. A Model of Paradoxical CRAF Activation
by BRAF
(A) In the presence of oncogenic RAS, BRAF is cytosolic,
where it maintains itself in an inactive conformation in
a manner that depends on its own kinase activity. CRAF
is recruited to the plasma membrane by RAS and activates
the pathway.
(B) When BRAF is inhibited by genetic or chemical means,
it is no longer autoinhibited and is recruited to the plasma
membrane by RAS, where it binds to CRAF. Although
BRAF does not itself signal, it can act as a scaffold to
enhance CRAF activity and consequently enhance sig-
naling through the pathway.
(C) Pan-RAF inhibitors hyperactivate CRAF because
they inhibit BRAF, but they simultaneously inhibit CRAF,
leading to paradoxical activation of CRAF without pathway
activation.
(D) T421NCRAF (T421N) escapes the paradoxical activation
by the pan-RAF inhibitors, because it no longer allows
them to bind, so is freely activated due to BRAF inhibition.networks function to fully comprehend how patients may
respond to targeted drugs. They also highlight the importance
of genetic screening for patients, not only to identify those who
are likely to respond, but to exclude those who could experience
adverse effects and thereby ensure successful implementation
of personalized medicine.
EXPERIMENTAL PROCEDURES
Reagents
Expression vectors for epitope-tagged BRAF and CRAF have been described
(Wan et al., 2004). For western blotting the following antibodies were used:
rabbit anti-ppMEK1/2 and mouse anti-myc 9B11 (Cell Signaling Technology);
mouse anti-NRAS (C-20), rabbit anti-ERK2 (C-14), rabbit anti-ARAF (C-20),
mouse anti-BRAF (F-7) (Santa Cruz Biotechnology); mouse anti-Tubulin,
and mouse anti-ppERK1/2 (Sigma); mouse anti-CRAF (for western blotting)
(BD Transduction Laboratories). For immunoprecipitation, the following anti-
bodies were used: rabbit anti-myc (Abcam); rabbit anti-CRAF (C-20;Santa
Cruz Biotechnology); mouse anti-BRAF (F-7) (Ab from Santa Cruz Biotech-
nology). Calf intestinal phosphatase (CIP) was from New England Biolabs
(NEB). PD184352, sorafenib and PLX4720 were synthesized in-house; 885-A
was synthesized by Evotec AG (Abingdon, UK). All drugs were prepared in
DMSO. Synthetic routes are available on request.Cell 140, 20Cell Culture Techniques
Human cell lines were cultured in DMEM (A375, WM852,
HCT116, SW620, and PMWK) or RPMI (D04, MM485,
MM415, and WM1791c) supplemented with 10% fetal
bovine serum. For protein depletion, 3 3 105 D04 cells
were transfected with 5nM CRAF (50-AAGCACGCTTAG
ATTGGAATA-30 ) or NRAS (50-CATGGCACTGTACTCTTC
TCG-30) specific, or scrambled control (50-AAACCGTC
GATTTCACCCGGG-30) siRNA using INTERFERin as
recommended by the manufacturer (Polyplus Transfection
SA). For transient expression studies, D04 cells were
transfected using the Amaxa Nucleofector System as
recommended by the manufacturer (Lonza). COS-7 cells
were propagated, transfected, and extracted as described
(Wan et al., 2004). For generation of stable lines, D04
cells were transfected with pMCEF-FLAG-CRAF or
pMCEF-FLAG-T421NCRAF using Effectene as recommen-
ded by the manufacturer (Invitrogen) and selected in
G418 (1 mg/ml).Cell lysates were prepared with NP40 buffer as described (Wan et al., 2004).
For immunoprecipitation, lysates were incubated with 2 mg BRAF F-7, 5 mg
CRAF C-20 or 2 mg rabbit anti-myc antibodies, captured on Protein G sephar-
ose 4B beads (Sigma) and analyzed by western blotting using standard
protocols. Specific bands were detected using fluorescent-labeled secondary
antibodies (Invitrogen; Li-COR Biosciences) and analyzed using an Odyssey
Infrared Scanner (Li-COR Biosciences). For CIP treatment, immunoprecipi-
tates were washed twice with NP40 lysis buffer, once in CIP buffer (50 mM
Tris-Cl [pH 7.5], 150 mM NaCl, 10 mM MgCl2, and 1 mM EDTA), and incubated
with CIP with or without 0.2 mM Na3VO4 and 7 mM EDTA. The immunoprecip-
itates were washed in CIP buffer and western blotted. Coupled RAF kinase
assays were performed with immunoprecipitated CRAF or BRAF as described
(Wan et al., 2004). Membrane fractionation was as described (Garnett et al.,
2005).
Transgenic Mice
Experiments were performed under Home Office license authority in accor-
dance with United Kingdom Coordinating Committee on Cancer Research
Guidelines (Workman et al., 1988) and with local Ethics Committee approval.
To activate CreERT2, mice were treated with four doses (10mg each) of topi-
cally applied tamoxifen as described (Dhomen et al., 2009). Genotyping was
performed by PCR. BrafLSL-D594A and BrafLox-D594A was analyzed as described
forBrafLSL-V600E andBrafLox-V600E respectively and Tyr::CreERT2was analyzed
as described (Dhomen et al., 2009). KrasLSL-G12D was analyzed using primers9–221, January 22, 2010 ª2010 Elsevier Inc. 219
50-CGCAGACTGTAGAGCAGCG-30 and 50-CCATGGCTTGAGTAAGTCTGC-30.
For expression analysis, RNA was prepared (QIAGEN RNEasy, QIAGEN) and
first-strand cDNA synthesis was performed with 500ng total RNA and random
hexanucleotides (Random Primers, Invitrogen). Specific genes were amplified
under linear conditions for analysis as described (Dhomen et al., 2009). For
Kras cDNA sequencing, a 238 bp fragment of Kras cDNA was PCR amplified
using primers 50-GGCGGCAGCGCTGTGGCGGCG-30 and 50-CGTAGGGTC
ATACTCATCCAC-30 and sequenced using automated dideoxy sequencing.
For immunohistochemistry (IHC), tissues were fixed and analyzed as
described (Dhomen et al., 2009). Positive (a well characterized sample of
mouse melanoma) and negative (omission of the primary antibody and substi-
tution with preimmune serum) controls were included in each slide run.
Immunohistochemical staining was analyzed by two of the authors on a
multi-headed microscope. Tumor cell lines were established by mechanically
dissociating tumors in DMEM/20%FCS/Primocin (0.1mg/ml - InvivoGen) and
clonal lines were selected by limiting dilution.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and three tables and can be found with this article online at doi:
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